Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01149109 : Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients
PhasePhase 3
AgesMin: 18 Years Max: 70 Years
Inclusion Criteria:

- written informed consent

- patients have to be in a cognitive state that allows them to understand the rationale
and necessity of study therapy and procedures.

- newly diagnosed histologically proven GBM or gliosarcoma WHO Grad IV

- methylated MGMT promoter in the tumor

- estimated life expectancy of at least 12 weeks

- Karnofsky Performance Score (KPS) ? 70%

- patient compliance and geographic proximity that allow adequate follow up

- male and female patients with reproductive potential must use an approved
contraceptive method

- pre-menopausal female patients with childbearing potential: a negative serum
pregnancy test must be obtained prior to treatment start

- Adequate organ function as described below:

Adequate bone marrow reserve:

white blood cell (WBC) count > 3000/µl, granulocyte count >1500/µl, platelets >
100000/µl, haemoglobin ? 10 g/dl Adequate liver function bilirubin < 1.5 times above upper
limit of normal range (ULN), ALT and AST < 3 times ULN creatinine < 1.5 times ULN

Adequate blood clotting:

PT and PTT within normal limits Negative HIV test

Exclusion Criteria:

- prior malignancy

- prior chemotherapy

- prior radiotherapy to the brain

- concurrent administration of any other anti-tumor therapy

- allergy or other intolerability of temozolomide, CCNU, dacarbazine or other
nitrosourea derivatives

- unable to undergo MRI

- past medical history of diseases with poor prognosis

- known HIV infection, active Hepatitis B or C infection

- any active infection

- female patients that are pregnant or breastfeeding

- patients with reproductive potential who do not accept to use contraception

- treatment in another clinical trial

- any psychological, cognitive, familial, sociological or geographical condition
potentially hampering compliance with the study protocol and follow-up scheduled
visits (at the discretion of investigator)
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557